標(biāo)題: Titlebook: Cardio-Oncology; Management of Toxici Antonio Russo,Nicola Maurea,Antonio Giordano Book 2022 The Editor(s) (if applicable) and The Author(s [打印本頁] 作者: 明顯 時間: 2025-3-21 16:41
書目名稱Cardio-Oncology影響因子(影響力)
書目名稱Cardio-Oncology影響因子(影響力)學(xué)科排名
書目名稱Cardio-Oncology網(wǎng)絡(luò)公開度
書目名稱Cardio-Oncology網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cardio-Oncology被引頻次
書目名稱Cardio-Oncology被引頻次學(xué)科排名
書目名稱Cardio-Oncology年度引用
書目名稱Cardio-Oncology年度引用學(xué)科排名
書目名稱Cardio-Oncology讀者反饋
書目名稱Cardio-Oncology讀者反饋學(xué)科排名
作者: chuckle 時間: 2025-3-21 22:05 作者: Collar 時間: 2025-3-22 02:20 作者: 陰險 時間: 2025-3-22 07:29
Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist,iological toxicities. Different types of cardiotoxicity can also occur with cell-based immune-therapy treatments (e.g., CAR-T), requiring specific diagnosis and management protocols. Because of the high morbidity and mortality, an early diagnosis of cardiological irAEs is essential for framing the o作者: phlegm 時間: 2025-3-22 12:44 作者: CHIDE 時間: 2025-3-22 16:27 作者: CHIDE 時間: 2025-3-22 18:36 作者: Outshine 時間: 2025-3-22 23:07 作者: 祖?zhèn)?nbsp; 時間: 2025-3-23 05:06
Atemwegssicherung, Intubation und Beatmung,ligand-1 (PD-L1) checkpoint inhibitors have a crucial role in oncological treatments, resulting in an improvement of progression-free survival (PFS) and overall survival (OS) compared with standard treatments. Moreover, different safety analyses established that immunotherapy is well-tolerated with 作者: 結(jié)構(gòu) 時間: 2025-3-23 06:12
,St?rungen der Vitalfunktionen,scular system. The most clinically relevant cardiovascular adverse event is myocarditis, with an incidence rate ranging from 0.27% of patients treated with single-agent ICIs up to 2.4% of patients treated with combinations. Immune-related myocarditis is burdened by high mortality, with a fatality ra作者: Acetaldehyde 時間: 2025-3-23 13:25 作者: 陪審團每個人 時間: 2025-3-23 14:47 作者: 地名詞典 時間: 2025-3-23 20:10
,Gastrointestinale und abdominale Notf?lle,scular complications. Immunotherapy is associated with a spectrum of side effects termed “immune-related adverse events” that include dermatologic, gastrointestinal, hepatic, and endocrine events. Temporary immunosuppression with glucocorticoids, tumor necrosis factor alpha antagonists, and mycophen作者: 吹牛者 時間: 2025-3-24 01:51
https://doi.org/10.1007/b137669erent cancers at the cost of possible adverse events, mostly based on immune activation against normal tissues. Most common immune-related adverse events (irAEs) are cutaneous, endocrinological, pulmonary, and gastrointestinal. Cardiovascular irAEs are much less frequently reported but burdened by h作者: Crumple 時間: 2025-3-24 05:58 作者: GULF 時間: 2025-3-24 08:06 作者: 兇殘 時間: 2025-3-24 10:47
Antonio Russo,Nicola Maurea,Antonio GiordanoProvides a complete and updated state-of-art review.Written by experts in the field.Addresses the future perspectives in the cardio-immunology field作者: 把手 時間: 2025-3-24 16:23 作者: 背景 時間: 2025-3-24 22:45 作者: Ovulation 時間: 2025-3-24 23:33 作者: ornithology 時間: 2025-3-25 05:14
Cardiac Risk Factors for Immunotherapy,y recognized risk factors combined with immunotherapy may increase the risk of cardiac injury. Therefore, it is important to assess a patient’s overall cardiovascular risk and treat any underlying cardiovascular conditions before commencing immunotherapy.作者: 最高點 時間: 2025-3-25 09:48
Book 2022eceptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC).?This volume provides a c作者: FRAX-tool 時間: 2025-3-25 14:16
Atemwegssicherung, Intubation und Beatmung,dentification of predictive biomarkers represents a crucial need in the oncological field. In this chapter, we summarize the available immunotherapy drugs in oncology with a special focus on future multimodal therapy.作者: 意外 時間: 2025-3-25 17:11 作者: 送秋波 時間: 2025-3-25 21:09
,Gastrointestinale und abdominale Notf?lle,e T-cell function in the lymph nodal and peripheral tissues. In this context, the complex interplay between cancer and the immune tumor microenvironment could crucially affect the outcome of immunotherapy while activating autoreactive T cells and resulting in a wide range of immune-related adverse events.作者: 鳴叫 時間: 2025-3-26 01:42
Atemwegssicherung, Intubation und Beatmung,fect of all the possible covariates that can reduce the informative power of these assays. Therefore, this chapter is aimed at focusing on the main data in favour of the use of troponin and natriuretic peptides in the setting of cardiotoxicity.作者: addition 時間: 2025-3-26 07:40
Background: Immunology and Cancer,e T-cell function in the lymph nodal and peripheral tissues. In this context, the complex interplay between cancer and the immune tumor microenvironment could crucially affect the outcome of immunotherapy while activating autoreactive T cells and resulting in a wide range of immune-related adverse events.作者: 被告 時間: 2025-3-26 11:38
Biomarkers of Early Cardiotoxicity,fect of all the possible covariates that can reduce the informative power of these assays. Therefore, this chapter is aimed at focusing on the main data in favour of the use of troponin and natriuretic peptides in the setting of cardiotoxicity.作者: Munificent 時間: 2025-3-26 13:15 作者: 柔軟 時間: 2025-3-26 18:42
,St?rungen der Vitalfunktionen,te of 40–50%. Other forms of cardiovascular toxicity include noninflammatory myocardial dysfunction, pericardial disease, arrhythmias, vasculitis, and myocardial infarction. In this chapter, the characteristics of immunotherapy cardiovascular adverse events are described.作者: Harass 時間: 2025-3-26 21:54
,Grundlegende notfallmedizinische Ma?nahmen,y recognized risk factors combined with immunotherapy may increase the risk of cardiac injury. Therefore, it is important to assess a patient’s overall cardiovascular risk and treat any underlying cardiovascular conditions before commencing immunotherapy.作者: Solace 時間: 2025-3-27 05:06
Background: Immunology and Cancer,Several different therapeutic approaches have consistently reported durable responses, showing that cancer immunotherapy is a promising and active treatment modality. Immune-related approaches have been associated with manageable safety profiles that are different from traditional therapies. In this作者: 親愛 時間: 2025-3-27 08:21 作者: defeatist 時間: 2025-3-27 10:46 作者: GLOOM 時間: 2025-3-27 13:55
Cardiac Risk Factors for Immunotherapy,atment, alone or in combination. The most common cardiac manifestation is myocarditis followed by pericardial diseases, conduction disorders, and arrhythmias. Although we lack the means to identify patients at high or low risk of immunotherapy-induced cardiotoxicity, it is feasible that the currentl作者: muscle-fibers 時間: 2025-3-27 19:08
Biomarkers of Early Cardiotoxicity,er drugs are available, the validation of these markers is still challenging, above all when applied to the early identification of severe cardiac side effects. Some biomarkers have been tested for this purpose, but only troponins and natriuretic peptides seem to play a role in clinical routine sett作者: Inkling 時間: 2025-3-27 22:29
Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist,scular complications. Immunotherapy is associated with a spectrum of side effects termed “immune-related adverse events” that include dermatologic, gastrointestinal, hepatic, and endocrine events. Temporary immunosuppression with glucocorticoids, tumor necrosis factor alpha antagonists, and mycophen作者: 合唱團 時間: 2025-3-28 02:36 作者: landmark 時間: 2025-3-28 06:53
9樓作者: 半身雕像 時間: 2025-3-28 13:31
9樓作者: BACLE 時間: 2025-3-28 17:31
10樓作者: 躲債 時間: 2025-3-28 20:41
10樓作者: irreparable 時間: 2025-3-29 00:17
10樓作者: 仇恨 時間: 2025-3-29 06:30
10樓
